CDSCO approval granted for New Drug for Diabetic Foot Ulcers

The CDSCO approval of this new drug is a beacon of hope for countless DFU patients.

7
CDSCO Central Drug Standard Control Organisation
CDSCO

Last Updated on July 26, 2024 by The Health Master

CDSCO approval

CDSCO approval: Diabetic foot ulcers, a severe complication of chronic diabetes, have been a persistent challenge for millions worldwide.

In India alone, a staggering 100,000 people suffer from lower limb amputations annually due to this condition.

The urgent need for effective treatments has driven pharmaceutical research, and a significant breakthrough has emerged.

NovaLead Pharma’s Innovative Solution

NovaLead Pharma, a pioneer in drug repurposing, has announced a major milestone in the fight against diabetic foot ulcers.

The company has received CDSCO approval from the Central Drugs Standard Control Organization (CDSCO) for its patented repurposed drug designed specifically for treating DFU.

This groundbreaking medication is a novel topical gel formulation of Esmolol hydrochloride, a substance already recognized for its efficacy in managing cardiac conditions when administered intravenously.

NovaLead’s innovation lies in repurposing this drug and developing a topical gel, marking a first-of-its-kind approach to DFU treatment.

Potential to Revolutionize DFU Management

The CDSCO approval of this new drug is a beacon of hope for countless DFU patients.

It could potentially revolutionize the management of this debilitating condition, reducing the risk of amputations and improving the quality of life for millions.

Government Support and Future Plans

It’s noteworthy that the development of this life-changing drug was partially funded by the Biotechnology Industry Research Assistance Council (BIRAC), a testament to the Indian government’s commitment to healthcare innovation.

NovaLead Pharma has secured patents for this drug in key markets like the USA, EU, and Japan, highlighting the global significance of their discovery.

The company plans to make the drug accessible to Indian patients through an exclusive IP licensing arrangement.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news